Company Description
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.
The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates.
Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 11, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Dr. David Alan Campbell Ph.D. |
Contact Details
Address: 10955 Vista Sorrento Parkway, Suite 200 San Diego, California 92130 United States | |
| Phone | (858) 751-4493 |
| Website | januxrx.com |
Stock Details
| Ticker Symbol | JANX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001817713 |
| CUSIP Number | 47103J105 |
| ISIN Number | US47103J1051 |
| Employer ID | 82-2289112 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Alan Campbell Ph.D. | President, Chief Executive Officer and Director |
| Byron Robinson J.D., Ph.D. | Chief Strategy Officer |
| Tighe M. Reardon C.F.A., CPA | Acting Chief Financial Officer |
| Charles M. Winter | Chief Technical Officer |
| Dr. Tommy Diraimondo Ph.D. | Chief Scientific Officer |
| James Pennington | General Counsel |
| Brenda Van Vreeswyk | Head of Human Resources |
| Andy Hollman Meyer | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 8, 2024 | 10-K | Annual Report |
| Mar 8, 2024 | 8-K | Current Report |
| Mar 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 4, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 29, 2024 | 424B5 | Filing |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 29, 2024 | FWP | Free Writing Prospectus |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 424B5 | Filing |